retatrutide triple agonist phase 2 obesity trial Associated with Weight Loss of up to 24% in 48-Week Triple hormone receptor agonist retatrutide

Although extremely rare, there have been cases where people have developed a redness or a rash around the injection site indicating a Vitamin B12 allergy

Slower stomach emptying can change the rate and extent of phentermine absorption, potentially altering its peak blood levels and duration of action

But the caveat always caveats

We targeted the incretin hormone GLP-1 due to its well-established impact on satiety and hyperglycemia, described in detail in a recent review 18

This seems counterintuitiveand there are some valid concerns about giving a drug that makes people less hungry to those already consuming too little